Last reviewed · How we verify
Pneumococcal 7-valent conjugate vaccine
This vaccine stimulates the immune system to produce antibodies against 7 serotypes of Streptococcus pneumoniae by presenting pneumococcal polysaccharide antigens conjugated to a protein carrier.
This vaccine stimulates the immune system to produce antibodies against 7 serotypes of Streptococcus pneumoniae by presenting pneumococcal polysaccharide antigens conjugated to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and young children, Prevention of pneumococcal otitis media and pneumonia in pediatric populations.
At a glance
| Generic name | Pneumococcal 7-valent conjugate vaccine |
|---|---|
| Also known as | PCV, Prevnar®, Prevnar |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (serotypes 4, 6B, 9V, 14, 18C, 19F, 23F) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains purified capsular polysaccharides from 7 serotypes of pneumococcus conjugated to diphtheria toxoid protein. This conjugation enhances immunogenicity by converting T-cell-independent antigens into T-cell-dependent antigens, enabling robust antibody responses and immunological memory. The resulting antibodies opsonize pneumococcal bacteria, facilitating complement activation and phagocytic clearance.
Approved indications
- Prevention of invasive pneumococcal disease in infants and young children
- Prevention of pneumococcal otitis media and pneumonia in pediatric populations
Common side effects
- Local injection site reactions (erythema, swelling, induration)
- Fever
- Irritability or fussiness
- Drowsiness
- Decreased appetite
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Nasopharyngeal Carriage of S. Pneumoniae (NA)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: